Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/EUCTR2008-006939-13-FR
EUCTR2008-006939-13-FRActive, not recruitingPhase 1

A RANDOMIZED, PHASE II, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE SAFETY AND ACTIVITY OF MetMAb, A MONOVALENT ANTAGONIST ANTIBODY TO THE RECEPTOR MET, ADMINISTERED TO PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER, IN COMBINATION WITH TARCEVA®(ERLOTINIB)

Genentech, Inc.0 sites120 target enrollmentStarted: April 1, 2009Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions
Drugs

Trial Snapshot

Phase
Phase 1
Status
Active, not recruiting
Enrollment
120
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional clinical trial of medicinal product

Eligibility Criteria

Sex
All

Inclusion Criteria

  • •Patients must meet the following criteria for study entry:
  • •Signed, written informed consent prior to any study-specific screening procedures
  • •Age = 18 years of age
  • •ECOG performance status of 0, 1, or 2 (see Appendix D of the protocol)
  • •Histologically confirmed NSCLC
  • •Availability at the site of a representative formalin-fixed, paraffin-embedded tumor specimen that enabled the definitive diagnosis of NSCLC with adequate viable tumor cells in a tissue block (preferred) or 15 unstained, serial slides, accompanied by an associated pathology report is required prior to randomization. Cytological samples are not acceptable. If the archival tissue is neither sufficient nor available, the patient may still be eligible, upon discussion with the Medical Monitor, assuming the patient:
  • •Can provide at least = 5 unstained, serial slides
  • •Is willing to consent to and undergo a pre-treatment biopsy of the tumor
  • •Recurrent or progressive disease following at least one chemo containing regimen for Stage IIIB/IV disease
  • •Patients who receive neo-adjuvant and/or adjuvant therapy for Stage I-IIIa disease prior to their first-line regimen (for Stage IIIb/IV) are eligible for study participation, provided they also receive first-line therapy for Stage IIIb/IV disease
  • •At least one of the chemotherapy containing regimens (for any stage) must have been platinum-based
  • •Measurable disease in accordance with RECIST (see Appendix C of the protocol)
  • •At least one measurable lesion on a pre-treatment FDG-PET scan that is also a target lesion on CT according to RECIST (as determined by the site)
  • •At the time of the interim analysis, the IRF will decide whether additional PET imaging should be obtained on remaining patients and at which sites, if not in all. Following input from the IRF, this criterion may only apply to sites that will continue to perform FDG-PET imaging (see protocol Section 4.5.6).
  • •Use of an acceptable means of contraception for men and women of childbearing potential
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1.2 Adults (18-64 years) yes
  • •F.1.2.1 Number of subjects for this age range
  • •F.1.3 Elderly (>=65 years) yes
  • •F.1.3.1 Number of subjects for this age range

Exclusion Criteria

  • •Patients who meet any of the following criteria will be excluded from study entry:
  • •More than two prior treatments for Stage IIIB/IV
  • •A change of chemotherapy regimen for reasons of patient intolerance or excessive toxicity does not constitute an additional regimen, unless disease progression was documented at the time of treatment change.
  • •Combined treatment with chemotherapy and radiation constitutes a single prior regimen
  • •Surgery does not constitute a prior regimen
  • •More than 30 days of exposure to an investigational or marketed agent that can act by EGFR inhibition, or a known EGFR-related toxicity resulting in dose modifications
  • •EGFR inhibitors include (but are not limited to) gefitinib, erlotinib, and cetuximab
  • •Chemotherapy, biologic therapy, radiotherapy or investigational drug within 28 days prior to randomization
  • •Exceptions are kinase inhibitors, which may be used within 2 weeks prior to randomization, provided that any drug-related toxicity has adequately resolved and prior approval has been obtained from the Medical Monitor
  • •Untreated and/or active (progressing or requiring anticonvulsants or corticosteroids for symptomatic control) CNS metastasis
  • •Patients with history of brain metastasis may be eligible for study participation, as long as they meet the following criteria:
  • •Measurable disease outside the CNS, as defined by RECIST
  • •No radiographic evidence of interim progression between the completion of CNS-directed therapy and the screening radiographic study
  • •Adequate CNS-directed treatment, which may include neurosurgery or stereotactic radiosurgery.
  • •The screening of CNS radiographic study is = 4 weeks since completion of radiotherapy and = 2 weeks since the discontinuation of corticosteroids and anticonvulsants
  • •Radiotherapy and/or stereotactic radiosurgery must be completed =4 weeks prior to Day 1
  • •Neurosurgery must be completed = 24 weeks prior to Day 1, and brain biopsy must be completed = 12 weeks prior to Day 1
  • •History of serious systemic disease within the past 6 months prior to randomization, including myocardial infarction, uncontrolled hypertension (blood pressure > 150/100 mmHg on medication), unstable angina, New York Heart Association (NYHA) Grade II or greater congestive heart failure, unstable symptomatic arrhythmia requiring medication (patients with chronic atrial arrhythmia, i.e., atrial fibrillation or paroxysmal supraventricular tachycardia are eligible), or Grade II or greater peripheral vascular disease
  • •Uncontrolled diabetes as evidenced by fasting serum glucose level > 200mg/dL
  • •Major surgical procedure or significant traumatic injury within 28 days prior to randomization
  • •Anticipation of need for a major surgical procedure during the course of the study
  • •Local palliative radiotherapy within 7 days prior to randomization or persistent adverse effects from radiotherapy that have not been resolved to Grade II or less prior to randomization
  • •Inability to take oral medication or requirement for intravenous (IV) alimentation or total parenteral nutrition with lipids, or prior surgical procedures affecting gastrointestinal absorption
  • •Symptomatic hypercalcemia requiring continued use of bisphosphonate therapy
  • •Patients who are receiving bisphosphonate therapy specifically to prevent skeletal events and who do not have a history of clinical significant hypercalcemia are eligible
  • •Any of the following abnormal hematologic values (within 2 weeks prior to randomization)
  • •ANC < 1,500 cells/µL
  • •Platelet count < 100,

Investigators

Similar Trials

Active, not recruiting
Phase 1
A study to evaluate the efficacy and the safety of MetMAb in combination with either bevacizumab + platinum + paclitaxel or pemetrexed + platinum in lung cancer patients (non-squamous non-small cell lung cancer).MET DIAGNOSTIC-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC)MedDRA version: 14.1 Level: LLT Classification code 10025054 Term: Lung cancer non-small cell stage IIIB System Organ Class: 100000004864MedDRA version: 14.1 Level: LLT Classification code 10025055 Term: Lung cancer non-small cell stage IV System Organ Class: 100000004864MedDRA version: 14.1 Level: LLT Classification code 10025048 Term: Lung cancer non-small cell recurrent System Organ Class: 100000004864
EUCTR2011-003719-42-GBGenentech, Inc259
Active, not recruiting
Not Applicable
A study to evaluate the efficacy and the safety of MetMAb in combination with paclitaxel+cisplatin or paclitaxel+carboplatin in patients with either locally advanced or metastatic squamous cell lung cancer.
EUCTR2011-003720-12-ESF. Hoffmann-La Roche Ltd.110
Active, not recruiting
Phase 1
A clinical trial to evaluate the activity of a new targeted drug, onartuzumab, in patients with metastatic triple negative breast cancer
EUCTR2010-020101-32-GBGENENTECH, Inc.185
Active, not recruiting
Not Applicable
A study to evaluate the efficacy and the safety of MetMAb in combination with either bevacizumab + platinum + paclitaxel or pemetrexed + platinum in lung cancer patients (non-squamous non-small cell lung cancer).
EUCTR2011-003719-42-LVF. Hoffmann-La Roche Ltd.260
Active, not recruiting
Not Applicable
A study to evaluate the efficacy and the safety of MetMAb in combination with paclitaxel+cisplatin or paclitaxel+carboplatin in patients with either locally advanced or metastatic squamous cell lung cancer.MET DIAGNOSTIC-POSITIVE NON-SMALL CELL LUNG CANCER(NSCLC)MedDRA version: 14.1Level: LLTClassification code 10025054Term: Lung cancer non-small cell stage IIIBSystem Organ Class: 100000004864MedDRA version: 14.1Level: LLTClassification code 10025055Term: Lung cancer non-small cell stage IVSystem Organ Class: 100000004864MedDRA version: 14.1Level: LLTClassification code 10025048Term: Lung cancer non-small cell recurrentSystem Organ Class: 100000004864
EUCTR2011-003720-12-DEF. Hoffmann-La Roche Ltd.110
A RANDOMIZED, PHASE II, MULTICENTER,... | Clinical Trial